% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • dwb1975 dwb1975 Mar 6, 2012 10:18 PM Flag

    Way Undervalued

    In July of last year Bayer agreed to $94 million for rights of torazolid in all markets except North America and Europe. That was before the recent study showing comparable results with better dosing schedule and shorter treatment coarse than linezolid. After the recent plummet in share price the rights to market torazolid in Europe and North America are worth well more than the market cap of this company ($140 million). My biggest concern is someone coming in and buying this company on the cheap. Their lead product is certain to be a billion dollar drug but this company may get taken over for <$6. Lets see some insider buying or some announcements to jack up the price a little. To have a drug this big only 1-2 years away from showtime is phenomenal. No debt, plenty of cash to finance until marketability. What am I missing here??

    SortNewest  |  Oldest  |  Most Replied Expand all replies